Navigation Links
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy

MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC. (NASDAQ: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a randomized, double-blind, multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofol disodium) Injection for sedation of patients undergoing bronchoscopy successfully met its primary endpoint of sedation success as well as all secondary endpoints. Among patients who received an initial bolus dose of 6.5 mg/kg of Aquavan, the sedation success rate was 88.7% compared to 27.5% of patients in the control arm (p less than 0.001). Results of this trial also indicate that the safety profile of the 6.5 mg/kg dose of Aquavan was predictable and similar to the safety profile of the control.

Data from the phase 3 bronchoscopy trial, together with the results from a phase 3 trial in patients undergoing colonoscopy and an open-label study in patients undergoing minor surgical procedures, will form the foundation of the Aquavan New Drug Application (NDA). MGI PHARMA plans to submit the Aquavan NDA to the U.S. Food and Drug Administration (FDA) early in the third quarter of 2007. As is consistent with standard medical practice, the three trials comprising the Aquavan pivotal program were conducted without monitored anesthesia care (MAC) sedation, and study drugs were administered by medical personnel as dictated by local investigative site guidelines.

"With more than 40 million procedures per year in the U.S. requiring moderate sedation, Aquavan may address a significant market opportunity," said Lonnie Moulder, President and Chief Executive Officer of MGI PHARMA. "The results of this pivotal program, together with completed pharmacokinetic studies, indicate that Aquavan has a pharmacokinetic and pharmacodynamic profile which may facilitate achievement and maintenance of targeted, controlled sedation by proceduralists. This unique profile may allow pati
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02343464/North-America-Laparoscopes-Market-Outlook-to-2020.html North ... GlobalData,s new report, "North America Laparoscopes Market ... the North America Laparoscopes market. The report provides ...
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
(Date:8/28/2014)... , Aug. 28, 2014 Tianyin ... ), a pharmaceutical company that specializes in patented ... and active pharmaceutical ingredients (API) today updates the ... Qionglai Facility (QLF). The Company ... (GMP) dataset for China Food & Drug Administration,s ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Some of the world,s largest pharmaceutical firms announced this ... in order to slash costs and keep investors happy, exposing ... AstraZeneca were the first to announce further job cuts with ... has already seen an extraordinary amount of job cuts over ...
... Md., Feb. 29, 2012  MedImmune today announced that ... approved FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) for ... early in the second quarter of last year.  ... approved by the FDA. All other ...
Cached Medicine Technology:Job Cuts from Major Pharmaceutical Firms Results in Tougher Competition, Says Advance Recruitment 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 3
(Date:8/29/2014)... 29, 2014 TayganPoint Consulting Group, a ... the second time, Inc. Magazine has named the company ... , Based on solid revenue growth of over 166% ... overall on the list. TayganPoint’s repeat success in ... the past few years, is a demonstration of its ...
(Date:8/29/2014)... Innovations Television, produced by DMG Productions, announced ... Innovations, focusing on health and elderly care, slated to air ... of Americans over 65 will nearly double by 2030, expanding ... 2030, for a total of 72 million people. Though many ... at least one chronic condition and use healthcare services more ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Fat is ... and bad fat. Brown fat is usually stored in the ... white fat typically reveals itself in overflowing bellies, muffin tops, ... fats occur naturally in many foods and promote better health, ... risks, including elevated bad cholesterol levels and lower good cholesterol ...
(Date:8/29/2014)... Scientists from four European countries say ... correlates with overall survival of mesothelioma. Surviving Mesothelioma has ... Click here to read it now. , Doctors ... cases of 523 mesothelioma patients who were ... [progression-free survival at 18 weeks after treatment] was strongly ...
(Date:8/29/2014)... Botanica Day Spa recently announced the ... menu along with a special introductory offer for the ... uses small glass cups to create a suctioning of ... a comfortable but effective pressure. The cups are then ... engage more tissue. In contrast, traditional massage primarily uses ...
Breaking Medicine News(10 mins):Health News:Innovations with Ed Begley, Jr., Seeking Content for Upcoming Series on Health and Elder Care 2Health News:Diet Doc Announces Modernized, Interesting and Easy to Follow Diet Plans that Deliver Fast Weight Loss and Teach Patients the Difference Between Good and Bad Fat 2Health News:Diet Doc Announces Modernized, Interesting and Easy to Follow Diet Plans that Deliver Fast Weight Loss and Teach Patients the Difference Between Good and Bad Fat 3Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2Health News:Cupping Massage Now Available at Botanica Day Spa in Clearwater, FL 2Health News:Cupping Massage Now Available at Botanica Day Spa in Clearwater, FL 3Health News:Cupping Massage Now Available at Botanica Day Spa in Clearwater, FL 4
... of adverse events for diabetes drug , , THURSDAY, Oct. ... should be banned in the United States because it ... other life-threatening risks that greatly outweigh its benefits, the ... said it has identified 14 cases of Avandia-induced liver ...
... epidemic is fueling the type 2 disease epidemic, officials say ... new cases of type 2 diabetes has nearly doubled in ... cases appearing in southern states, federal officials reported Thursday. , ... 1,000 people from 1995 to 1997 to 9.1 per 1,000 ...
... Pet Owners and Contribute to Research, BREA, ... sentence,for pets, cancer is claiming fewer four-legged victims ... of pet owners to pursue those,treatments. Veterinary Pet ... insurer, will seek to raise national awareness about ...
... Connextions Offers Best Practices and Lessons Learned from Other Industries, ... ... (PRWEB) October 30, 2008 -- Companies who have watched their ... or "Chat," are increasingly considering this technology for their own ...
... (Oct. 30, 2008) -- Weill Cornell Medical College announced ... Explorations grants from the Bill & Melinda Gates Foundation. ... "Untimely Triggering of the Fusion Mechanism Used by Viruses ... conducted by Dr. Anne Moscona, and "Senescent and Rejuvenated ...
... Interview Her Virtually at http://www.bodybymilk.com , WASHINGTON, ... graduating from high school, becoming a Billboard,chart-topping country super ... the Year, Swift has a hectic schedule. She knows ... she needs to stay in top shape. That,s,why she ...
Cached Medicine News:Health News:Consumer Group Seeks FDA Ban on Avandia 2Health News:Consumer Group Seeks FDA Ban on Avandia 3Health News:Rate of Diabetes Cases Doubles in 10 Years: CDC 2Health News:Rate of Diabetes Cases Doubles in 10 Years: CDC 3Health News:Veterinary Pet Insurance Kicks Off Fourth Annual Pet Cancer Awareness Month 2Health News:Veterinary Pet Insurance Kicks Off Fourth Annual Pet Cancer Awareness Month 3Health News:Companies Turn to Click-to-Chat Technology to Reduce Operating Expense and Enhance Customer Service 2Health News:Companies Turn to Click-to-Chat Technology to Reduce Operating Expense and Enhance Customer Service 3Health News:Companies Turn to Click-to-Chat Technology to Reduce Operating Expense and Enhance Customer Service 4Health News:Weill Cornell Medical College receives 2 $100,000 grants for innovative global health research 2Health News:Country Super Star Taylor Swift Stays Fearless With a Little Help From Milk 2
... Euclid Systems Orthokeratology (oprifocon A) Contact ... lenses used for orthokeratology, a process ... patient wears these lenses overnight and ... the day, nearsightedness is temporarily corrected ...
... rigid gas permeable contact lenses used for ... corrects nearsightedness (myopia). The patient wears the ... upon wakening. During the day, nearsightedness is ... and Quadra RG contact lenses apply slight ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... same as the model SP-8800 with one big exception. ... This mode has its own fixation targets to allow ... allows you to select an area on the cornea ... to calculate averages of multiple readings in any one ...
Medicine Products: